Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec 20:4:90.
doi: 10.1186/s40425-016-0188-z. eCollection 2016.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Michael Boyiadzis #  1 , Michael R Bishop #  2 , Rafat Abonour  3 , Kenneth C Anderson  4 , Stephen M Ansell  5 , David Avigan  6 , Lisa Barbarotta  7 , Austin John Barrett  8 , Koen Van Besien  9 , P Leif Bergsagel  10 , Ivan Borrello  11 , Joshua Brody  12 , Jill Brufsky  13 , Mitchell Cairo  14 , Ajai Chari  12 , Adam Cohen  15 , Jorge Cortes  16 , Stephen J Forman  17 , Jonathan W Friedberg  18 , Ephraim J Fuchs  19 , Steven D Gore  20 , Sundar Jagannath  12 , Brad S Kahl  21 , Justin Kline  22 , James N Kochenderfer  23 , Larry W Kwak  24 , Ronald Levy  25 , Marcos de Lima  26 , Mark R Litzow  27 , Anuj Mahindra  28 , Jeffrey Miller  29 , Nikhil C Munshi  30 , Robert Z Orlowski  31 , John M Pagel  32 , David L Porter  33 , Stephen J Russell  5 , Karl Schwartz  34 , Margaret A Shipp  35 , David Siegel  36 , Richard M Stone  4 , Martin S Tallman  37 , John M Timmerman  38 , Frits Van Rhee  39 , Edmund K Waller  40 , Ann Welsh  41 , Michael Werner  42 , Peter H Wiernik  43 , Madhav V Dhodapkar  44
Affiliations

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia

Michael Boyiadzis et al. J Immunother Cancer. .

Abstract

Increasing knowledge concerning the biology of hematologic malignancies as well as the role of the immune system in the control of these diseases has led to the development and approval of immunotherapies that are resulting in impressive clinical responses. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a hematologic malignancy Cancer Immunotherapy Guidelines panel consisting of physicians, nurses, patient advocates, and patients to develop consensus recommendations for the clinical application of immunotherapy for patients with multiple myeloma, lymphoma, and acute leukemia. These recommendations were developed following the previously established process based on the Institute of Medicine's clinical practice guidelines. In doing so, a systematic literature search was performed for high-impact studies from 2004 to 2014 and was supplemented with further literature as identified by the panel. The consensus panel met in December of 2014 with the goal to generate consensus recommendations for the clinical use of immunotherapy in patients with hematologic malignancies. During this meeting, consensus panel voting along with discussion were used to rate and review the strength of the supporting evidence from the literature search. These consensus recommendations focus on issues related to patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. Overall, immunotherapy is rapidly emerging as an effective therapeutic strategy for the management of hematologic malignances. Evidence-based consensus recommendations for its clinical application are provided and will be updated as the field evolves.

Keywords: Acute leukemia; Cancer immunotherapy; Hematologic malignancies; Immunotherapy; Lymphoma; Multiple myeloma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Table of the Cancer Immunotherapy Guidelines for Hematologic Malignancy participants. Asterisks (*) indicate panel chair and steering committee member
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311–9. doi: 10.1056/NEJMoa1411087. - DOI - PMC - PubMed
    1. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–98. doi: 10.1038/nrclinonc.2013.153. - DOI - PubMed
    1. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice G. In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, editors. Clinical Practice Guidelines We Can Trust. Washington (DC): National Academies Press (US) Copyright 2011 by the National Academy of Sciences. All rights reserved.; 2011 - PubMed
    1. Society for Immunotherapy of Cancer Cancer Immunotherapy Guidelines. https://www.sitcancer.org/resources/cancer-immunotherapy-guidelines.
    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2010;364(11):1046–60. doi: 10.1056/NEJMra1011442. - DOI - PubMed